Articles tagged with Cancer Medication
A comprehensive review of 241 gene variants and cancer risk identified only two statistically significant associations, including an XRCC1 allele and ERCC2 allele linked to lung cancer. The findings suggest that genetic risks are typically modest, and large-scale evidence is needed to establish specific associations.
Researchers at UC Davis Cancer Center have discovered a molecule called LXY1 that targets glioblastoma, a deadly form of brain cancer. The molecule binds to alpha-3 integrin on cancer cells, allowing for direct delivery of treatments and sparing normal tissues.
A new, portable ultrasound device created by Cornell graduate student George K. Lewis can treat prostate tumors and kidney stones by breaking them up, while also relieving arthritis pressure. The device is smaller, more powerful, and less expensive than traditional models, paving the way for its use in hospitals and medical research labs.
A recent study by Tel Aviv University researchers validates Prozac's potential in fighting cancer itself. Prozac dramatically enhances the effectiveness of doxorubicin, an anti-cancer drug, by blocking resistance mechanisms in cancer cells.
A team of researchers from VCU identified a new anti-tumor gene called SARI, which can inhibit the growth and survival of tumor cells by interfering with cancer cell molecules. The discovery highlights a previously unrecognized molecular pathway underlying the anti-tumor action of interferon.
Researchers at Michigan State University discovered a new method to analyze bacterial inclusion bodies using nuclear magnetic resonance spectroscopy. This breakthrough could streamline protein-based drug manufacturing, making it quicker and more efficient.
A growing number of older adults are expected to be diagnosed with and live longer with cancer due to the aging baby boomer population. Critical issues include prevention, screening, treatment, survivorship, and end-of-life care for older adults with cancer.
A Phase 2 clinical trial of pralatrexate found a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma. The treatment, which mimics folic acid, showed durable responses in patients who had failed multiple prior treatments.
Researchers have discovered an experimental drug that successfully blocks an enzyme causing certain bone marrow cancers. The oral drug, CYT387, was tested in mice and human cells, blocking the growth of myeloproliferative disorders and normalizing blood counts.
New treatments for advanced kidney cancer have shown promising results but are unlikely to be adopted in the UK due to high costs. The National Institute for Health and Clinical Excellence has provisionally ruled out using four new drugs, citing cost-effectiveness concerns.
A study published in Cancer Prevention Research suggests that selenium may aid in the prevention of high-risk bladder cancer. Women, moderate smokers, and those with p53 positive bladder cancer had significant reductions in bladder cancer with higher rates of selenium.
Researchers have discovered that simultaneous inhibition of BCR-ABL and KIT proteins is crucial for suppressing leukemia cell growth. This finding may lead to the development of novel drugs targeting multidrug resistant mutants of BCR-ABL, as well as new treatment strategies for CML stem cells.
A team of researchers has identified a crucial mechanism in cell division, which could lead to improved cancer therapies with fewer side effects. By understanding how the contractile ring pinches cells into two daughter cells, scientists can develop more targeted treatments.
A clinical trial at Ohio State University found that older AML patients responded well to a less toxic therapy, achieving complete remission in 42% of cases. The treatment involved decitabine and showed promising results for this 'silent majority' of patients who previously were told they had no chance of treatment.
A previously dismissed leukemia drug, flavopiridol, has shown promising results in treating CLL patients with advanced chromosomal abnormalities. In a two-phase trial involving 116 patients, approximately half responded to treatment.
A new prostate cancer drug, degarelix, has been shown to dramatically reduce testosterone levels in patients as early as three days after treatment. Compared to other treatments, degarelix also resulted in faster declines in prostate-specific antigen (PSA) levels and fewer side effects such as urinary tract infections and joint pains.
Researchers found that combining PI3K and MEK inhibitors led to significant tumor shrinkage in mice with lung cancer driven by K-Ras mutations. The combination treatment eradicated the tumors with minimal toxicity, providing a strong rationale for testing this therapy in human trials.
Researchers have discovered a peptide that converts the Bcl-2 protein from a cancer cell's friend to a foe, allowing it to kill cancer cells and shrink tumors. This breakthrough could lead to the development of new cancer-fighting drugs targeting Bcl-2.
Researchers found blood transfusions in hospitalized cancer patients increased venous thromboembolism (VTE) and arterial thromboembolism (ATE) rates, comparable to erythropoiesis-stimulating agents (ESAs). This study highlights the need for cautious use of transfusions and exploration of ways to reduce clot risk in cancer patients.
A Florida State University research team has discovered a crucial new layer of regulation in the cell division cycle, which could lead to better cancer diagnosis and treatment. The findings highlight the importance of Cdc14 protein enzyme in ensuring correct timing and order of cell-cycle events.
Four Americans, including US Senators Edward Kennedy and Mina Bissell, are being honored with the American Cancer Society's Medal of Honor for their outstanding contributions to cancer research and control. The recipients have made significant impact in funding, legislation, and awareness campaigns.
Researchers at Northwestern University found a way to trick the immune system of mice into believing transplanted islets are their own cells. This technique eliminated the need for immunosuppressive drugs in mice with chemically-induced diabetes after islet transplantation, showing high success rates.
The Texas Emerging Technology Fund has awarded a record $3.5 million to NanoMedical Systems Inc., a startup founded by Mauro Ferrari, to develop a Personalized Molecular Drug-Delivery System for controlled medicine release. The system aims to provide a safer and more reliable alternative to traditional injection methods.
A new strategy targets the cooperation among pathogens, which is more effective than killing individual cells with traditional drugs. By disrupting the teamwork, the immune system can combat any remaining infection.
A new class of compounds, phosphaplatins, can effectively kill various types of cancer cells, including ovarian, testicular and head and neck cancer cells, with potentially fewer side effects than conventional drugs like cisplatin and carboplatin.
A study found that 78% of breast cancer patients had at least one other cause of bone loss besides cancer drugs. Vitamin D deficiency was the most common factor, affecting 38% of breast cancer patients compared to 51% of non-cancer patients.
A nontoxic nanoparticle can enter cells, dissolve harmlessly, and release therapeutic drugs or fluorescent dyes. This delivery system has shown promise for treating cancer and vascular diseases.
Researchers at UCSF used kinase inhibitors to block and reverse type 1 diabetes in mice, showing potential for new therapeutic approach. The study found that 80% of mice with established diabetes reversed symptoms after two months of treatment.
Researchers found that cancer drugs imatinib and sunitinib can put type 1 diabetes into remission in 80% of test mice. The benefits of the drugs' rapid action are attributed to their ability to block platelet-derived growth factor receptor, a tyrosine kinase not known to be implicated in diabetes.
Researchers found that consumption of red meat introduces a non-human glycan molecule, promoting chronic inflammation and tumor growth. Anti-inflammatory treatment reduced tumor size in mice, suggesting a potential link between red meat and cancer risk.
Fox Chase researchers create bispecific antibody ALM that attacks two signaling proteins on breast cancer cell surfaces, halting growth. The molecule could deliver therapeutic drugs directly to cancer cells or aid in early detection.
A study found that African-American patients with non-small cell lung cancer have a higher copy number of the epidermal growth factor receptor (EGFR) gene, predicting better long-term outcomes when taking erlotinib and gefitinib. Few EGFR mutations were observed, highlighting the need for more research in this patient population.
Researchers found that patients with gastrointestinal stromal tumors (GIST) respond differently to medications depending on their unique genetic makeup. The study suggests that developing individualized treatment plans tailored to the specific mutations in each tumor could improve patient outcomes. Additionally, the analysis of Sutent'...
Dr. Gary J. Bennett's research focuses on understanding how chemotherapy drug paclitaxel causes neuropathy, a painful and debilitating side effect of cancer treatment. The $80,000 grant will support his two-year study to identify novel mechanisms and potentially lead to new therapeutic strategies.
Researchers found that blocking VEGF levels in a tumor props up existing blood vessels, making them stronger and more normal. This makes the tumor more susceptible to chemotherapy drugs, offering a new strategy for cancer treatment.
Researchers found that dense networks of blood vessels thought to promote cancer growth may actually hinder tumor progression. Tumors fed by more normal vascular were also more vulnerable to chemotherapy drugs.
Research suggests that vitamin D, specifically its active form calcitriol, could offer protection against radiation-induced damages by regulating cell cycle and proliferation. This could be a potential safe agent for protecting people before or after low-level nuclear incidents.
Researchers at Moores UCSD Cancer Center are conducting a clinical trial of an immune-boosting vaccine, ISF35, to combat chronic lymphocytic leukemia (CLL) in high-risk patients. The therapy aims to activate the immune system and eliminate cancer cells.
Better designed rodent trials could reduce the cost and time required for cancer drug development. A well-designed rodent study should include an appropriate animal model, correct statistical evaluation of data, proper randomization, and a sufficient number of animals.
Popular cholesterol-busting drugs statins appear to lower men's PSA values along with their cholesterol levels. However, it remains unclear whether statins prevent prostate cancer growth or just mask it. The study found that PSA levels declined by an average of about four percent after starting statins.
A review found that off-label use of anticancer drugs ranged from 6.7% to 33.2% between 1990 and 2002, primarily used in palliative care. The study highlights the need for accurate data on off-label use to inform decision-making by health professionals.
Frank L. Meyskens Jr., a renowned cancer prevention researcher, has received the AACR-Prevent Cancer Foundation Award for his significant contributions to the field. His work on chemoprevention, including the development of topical all-trans-retinoic acid for cervical intraepithelial neoplasia, has moved the field forward.
Preliminary trials of a new multi-kinase inhibitor, XL184, have indicated impressive tumour shrinkage activity in patients with advanced medullary thyroid cancer. The overall disease control rate was 84% in the 25 patients who have been followed for at least three months.
ANG1005, a proprietary peptide vector, transports paclitaxel across the blood-brain barrier with high efficacy. The drug has shown promising results in clinical trials for brain metastasis and malignant glioma, with increased survival rates and reduced tumor growth.
A new anti-cancer compound, BI 6727, has shown encouraging anti-tumour activity in a phase I clinical trial. The compound works by inhibiting the action of Polo-like kinase 1, leading to abnormal mitotic spindles and disrupting cell division.
Researchers at Dana-Farber Cancer Institute identified a trigger point on a naturally occurring death protein that helps the body get rid of unwanted or diseased cells. The newly found trigger may be exploited as a target for designer drugs that force malignant cells to commit suicide.
A University of Minnesota study has identified genetic markers associated with early clinical relapse of multiple myeloma. The research suggests that a patient's genetic background influences their prognosis and response to treatment, paving the way for individualized assessments and personalized therapies.
Researchers identified AHI-1 protein that protects leukemia stem cells from imatinib, a current treatment for CML. Blocking AHI-1 restores imatinib's ability to kill leukemia cells, paving the way for combination therapy.
A new computational approach developed by Tel Aviv University researchers may help scientists gain a clearer overall picture of the metabolic processes in different tissues. The model integrates tissue-specific information to predict metabolic tissue behavior, exposing the functions responsible for metabolism.
Researchers have identified genes that control cell death as contributing to age-related hearing loss. The study used mice to chart the activity of over 22,000 genes, finding eight genes involved in the apoptotic process whose activity differed between normal and hearing-loss mice.
Lucile L. Adams-Campbell, a renowned expert on health disparities, has been elected to the Institute of Medicine, recognized for her outstanding professional achievements and commitment to service. As a professor of oncology at Georgetown University Medical Center's Lombardi Comprehensive Cancer Center, she will strive to enhance the n...
Scientists have created a new compound that selectively kills cancer cells while sparing healthy cells, offering hope for more effective chemotherapy drugs. The compound targets cancer cells' high iron levels, delivering toxic molecules that ultimately lead to cell death.
Researchers discovered that the small intestine can detect bitter toxins in food, slowing digestion and producing hormones that suppress appetite. This finding has potential applications for treating ailments like cancer and diabetes, and may explain why certain populations adapt to eat local foods that are toxic to outsiders.
A landmark clinical trial is underway to test whether a low-molecule-weight heparin can prevent pulmonary embolism in patients receiving chemotherapy on an outpatient basis. The trial aims to identify high-risk cancer patients and demonstrate that blood clots can be prevented with anti-coagulant therapy.
A subset analysis of a randomized trial found that older patients with renal cell carcinoma derive similar clinical benefits from sorafenib therapy as younger patients, including improved progression-free survival and quality of life. The treatment was well-tolerated regardless of age, with manageable side effects.
A Northwestern University research team developed a nanomaterial-based biomedical device that delivers chemotherapy drugs locally to tumor sites, reducing unnecessary exposure to toxic drugs. The device takes advantage of nanodiamonds for sustained drug release, which was demonstrated to be effective for one month.
Researchers discovered how the gene mda-9/syntenin interacts with signaling protein c-Src to promote metastasis in human melanoma cells. This interaction triggers a signaling cascade resulting in increased cancer cell motility, invasion and metastasis.
Researchers identify a small molecule that blocks miR-21, a key player in brain and various types of cancer. The discovery offers new hope for developing targeted cancer therapies with fewer side effects.
Researchers at Baylor College of Medicine discovered three phosphatases that deactivate cancer-promoting molecule SRC-3. This finding provides a new target for cancer treatment and may lead to more effective drugs with fewer side effects.
The NIH Director's Pioneer Award program has made 63 awards, with the New Innovator Award program supporting 61 investigators. The grants enable recipients to pursue innovative approaches that could transform biomedical and behavioral science, with an estimated total value of up to $138 million over five years.